Trials / Completed
CompletedNCT05892926
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 204 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter non-interventional observational retrospective study with secondary data collection
Detailed description
It will be multicenter study. Planned number of study sites is about 50 oncological centers specialized on anticancer chemotherapy in various regions of Russia. A multi-center collaborative effort will help to describe characteristics of patients with HER2-positive gastric and/or GEJ adenocarcinoma in different regions in the most comprehensive way and to capture more patients into database, not only limited to a single institution
Conditions
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2023-06-07
- Last updated
- 2025-07-20
Locations
31 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05892926. Inclusion in this directory is not an endorsement.